All In Biotech

Drug Trial Radar · NCT04577352

A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich Ataxia (MOVE-FA)

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

146

Actual

Start

Dec 17, 2020

Primary completion

Apr 4, 2023

Study completion Oct 2, 2023

Sponsor

Lead sponsor
PTC TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy (using the modified Friedreich Ataxia Rating Scale \[mFARS\]) and safety of vatiquinone in participants with Friedreich ataxia (FA).

Conditions

  • Friedreich Ataxia

Interventions

  • VatiquinoneDrug

    Vatiquinone will be administered per dose and schedule specified in the arm.

  • PlaceboDrug

    Placebo will be administered per schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis SetTime frame: Baseline, Week 72
  2. Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis SetTime frame: Baseline, Week 72

Locations

14 sites in 9 countries. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California

  • University of Florida

    Gainesville, Florida

  • University of South Florida

    Tampa, Florida

  • University of Iowa

    Iowa City, Iowa

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • University of Campinas (UNICAMP) - School of Medical Sciences, Dept of Neurology

    São Paulo, Brazil

  • Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)

    Montreal, Quebec, Canada

  • CHU Sainte-Justine

    Montreal, Quebec, Canada

  • Hôpital Pitié-Salpêtrière, Institut du Cerveau (Paris Brain Institute)

    Paris, France

  • Department of Neurology and Hertie-Institute for Clinical Brain Research German Center of Neurodegenerative Diseases (DZNE)

    Tübingen, Germany

  • Ospedale Pediatrico Bambino Gesu' IRCCS

    Roma, Italy

  • CBR Neurogenetic Research Clinic, University of Auckland

    Auckland, New Zealand

  • Hospital Sant Joan de Déu Barcelona Unidad de Enfermedades Neuromusculares

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.